News Headlines Article

Roche revenue dips as Avastin sales fall
San Francisco Business Times

Declining sales of cancer drug Avastin, health care reform and a strong Swiss franc pushed down first-quarter revenue for Genentech Inc. parent Roche Holding AG by 9 percent, the company said. Avastin sales, measured in francs, dropped 15 percent, Roche said. Overall, Roche sales fell 9 percent to 11.1 billion francs, or $12.4 billion. About one-third of Roche’s sales come from the United States, Bloomberg reported, and Avastin is the world’s best-selling cancer drug.